Cleveland Rocks for Acreage Holdings, says Beacon Securities

Cleveland Rocks for Acreage Holdings, says one analyst.

News on an Ohio expansion for Acreage Holdings (Acreage Holdings Stock Quote, Chart, News CSE:ACRG.U) has Beacon Securities analyst Russell Stanley maintaining his “Buy” rating on the stock.

This morning, Acreage announced it had opened two new cannabis dispensaries in Ohio, one in Cleveland and the other in Columbus, through partner Greenleaf Apothecaries LLC. The firm now has 28 dispensaries in 11 states.

Stanley says these new openings max out Acreage Holdings’ retail footprint in Ohio.

“Earlier today, Acreage announced recent grand openings of two dispensaries by the company’s local partner, Greenleaf Apothecaries. As discussed in Our October 15th note, the company recently entered a settlement with the Ohio Board of Pharmacy that called for the regulator to complete final inspections for these locations by the end of October. This morning’s press release confirms that those inspections were completed, allowing these locations to open earlier this week. According to the Board of Pharmacy’s data, Greenleaf has received certificates of operation (COA) for the state maximum of five dispensaries, including four locations operating under The Botanist brand. This includes locations in Cleveland, Columbus, Akron, Canton and Wickliffe.”

The analyst says despite a slow start, this market has all the right ingredients.

The state has thus far issued 56 provisional dispensary licenses, of which 44 have been issued COAs allowing them to open. As of October 17th, the program had almost 64,000 registered patients, and almost 41,000 had made purchases. While this market has opened more slowly than many predicted, we continue to expect it will develop into one of the strongest medical markets in the US. Its population of 11.7M ranks it 7th largest in the US, and its list of allowable medical conditions could allow approximately 3.5M residents (30% of the state) to qualify for medical cannabis use.

In a research update to clients today, Stanley maintained his “Buy” rating and one-year price target of (US) $27.00 for Acreage Holdings, implying a return of 344 per cent at the time of publication.

Stanley thinks ACRG will post Adjusted EBITDA of negative $4.0-million on revenue of $145.0-million in fiscal 2019. He expects those numbers will improve to EBITDA of positive $118.0-million on a topline of $473.0-million the following year.

“ACRG is now trading at a 48% discount to the implied value of the Canopy acquisition price, as of last night’s close,” the analyst added.

In October, Greenleaf resolved its dispute with the state of Ohio which in July alleged that it had violated state ownership rules.

““We are thrilled to share the news that Greenleaf Apothecaries has resolved its dispute with the Ohio Board of Pharmacy in a way that allows Greenleaf to open its remaining three dispensaries in Cleveland, Columbus, and Akron, while maintaining its relationship with Acreage Holdings,” Acreage Chairman and CEO Kevin Murphy said. “As part of our consulting relationship with Greenleaf, which includes a licensing agreement, all five of their dispensaries will be called The Botanist.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: acrg.u
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

14 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

21 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

22 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

23 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago